Bretylum en es it fr

Bretylum Brand names, Bretylum Analogs

Bretylum Brand Names Mixture

  • No information avaliable

Bretylum Chemical_Formula


Bretylum RX_link

Bretylum fda sheet

Bretylum msds (material safety sheet)

Bretylum MSDS

Bretylum Synthesis Reference

No information avaliable

Bretylum Molecular Weight

243.163 g/mol

Bretylum Melting Point

No information avaliable

Bretylum H2O Solubility

Freely soluble

Bretylum State


Bretylum LogP

No information avaliable

Bretylum Dosage Forms

Solution for injection (50mg/mL)

Bretylum Indication

For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

Bretylum Pharmacology

Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.

Bretylum Absorption

No information avaliable

Bretylum side effects and Toxicity

Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.

Bretylum Patient Information

Bretylum Organisms Affected

Humans and other mammals